截至最后实际可行日期，公司的核心产品包括LNK01001，一款高选择性、有潜力成为同类最佳的第二 代JAK1抑制剂，以及LNK01004，一款有潜力成为同类首创的第三代软性泛JAK抑制剂，靶向自身免疫 及炎症疾病。公司的关键产品LNK01006是一款尖端、高选择性并可穿透中枢神经系统的别构TYK2抑 制剂，靶向中枢神经系统的相关疾病。此外，公司建立创新专有IsoNova蛋白降解平台，其采用稳健的 单分子设计，可消除非活性异构体，从而提供更清晰、更优良的安全度。 据联交所11月30日披露，凌科药业(浙江)股份有限公司向联交所提交上市申请，拟香港主板上市，中信 证券(香港)有限公司、建银国际金融有限公司为联席保荐人。 公司是自身免疫及炎症疾病的创新差异化小分子抑制剂的领先开发商。公司的临床管线主要集中于 Janus激酶-讯号转导及转录激活因子(JAK-STAT)的信号通路。 注：本文系新闻报道，不构成投资建议 ...

Core Viewpoint - The company has successfully established an evaluation scheme for in vitro STAT6 inhibitors/degraders, aiding in the development of drugs targeting STAT6 for autoimmune diseases [1] Group 1: Company Developments - The in vitro pharmacological efficacy department of the company has developed a new evaluation scheme [1] - The focus of the evaluation scheme is on STAT6, a key member of the JAK-STAT signaling pathway [1] Group 2: Scientific Background - STAT6 acts as a transcriptional regulatory hub for the IL-4/IL-13 signaling pathway [1] - It plays a crucial role in immune processes such as Th2 cell differentiation and IgE class switching [1] - The protein is significant in regulating immune homeostasis and the pathological processes of autoimmune diseases [1]